- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of January 20
The Center for Biosimilars® recaps the top stories for the week of January 20, 2020.
Hi, I’m Gianna Melillo for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of January 20, 2020
Number 5: Celltrion announces that it plans to launch 10 biosimilars over the next decade and will also open a large biologics manufacturing plant in China.
Number 4: A healthcare executive writes that providers should be able to help their patients reduce their out-of-pockets costs while providing the highest-quality care available through oncology biosimilars.
Number 3: Alvotech and JAMP Pharma announce a partnership to commercialize 5 biosimilars in the Canadian market.
Number 2: Gilead Science’s new chairman and chief executive officer outlines a growth plan at the J.P. Morgan Healthcare Conference.
Number 1: Teva Pharmaceuticals touts the launch of its biosimilar rituximab, Truxima, as evidence that it knows how to navigate the US pharmaceutical system.
To read all of these articles and more, visit centerforbiosimilars.com.
Duke Publishes Recommendations for Developing CGT Biosimilars
October 9th 2024Transformative cell and gene therapies (CGT) offer promising treatments for serious conditions, but high costs and complex biologics limit competition, requiring policies that support the development of biosimilars to enhance affordability and patient access.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
BioRationality—The Evolution of the BPCIA and the Bright Future of Biosimilars in the US
October 7th 2024The Biologics Price Competition and Innovation Act (BPCIA) of 2010 initially posed significant barriers to biosimilar development, but regulatory reforms over the years have drastically reduced costs and approval times, with further advancements expected by 2025 that will foster competition and drive down prices.
